Cerebral and bone multidrug resistant tuberculosis treated with the BPaLM regimen: case report
Frontiers in Pharmacology · 12.05.2026 · 17
DOI: 10.3389/fphar.2026.1796484 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.05.2026. Verfasst von Marina Calamelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, Clinic of Infectious and Tropical Diseases, ASST Spedali Civili Hospital, University of Brescia, Br…. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The BPaLM regimen is recommended for the treatment of pulmonary and extrapulmonary multidrug resistant tuberculosis, with the exception of cerebral and bone localization due to uncertainties on adequate drug concentrations in these tissues.
Methods
We report two MDR-TB cases with cerebral and bone disease treated with BPaLM at the Clinic of Infectious and Tropical Diseases in Brescia, Italy. Clinical data were collected through a comprehensive review of the electronic medical records, diagnostic results and patient interviews. The patients provided written informed consent for the publication of clinical data in anonymous form.
Results
Patient 1, affected by disseminated TB involving lungs, lymph nodes and bones, completed 7 months of therapy, six of which with the BPaLM regimen, and demonstrated no evidence of relapse at 1-year follow-up. Patient 2, presenting with disseminated TB including cerebral and bone localisation, received the BPaLM regimen that was discontinued after 4 months due to adverse events.
Discussion
Our report contributes to the limited clinical evidence on the use of BPaLM in cerebral and bone RR/MDR-TB. Of the two patients treated with this regimen, one did not complete therapy; however, treatment interruption was attributable to adverse events rather than lack of efficacy. Further evidence is urgently required on shorter regimens such as BPaLM for the treatment of extrapulmonary tuberculosis involving the brain and bones.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Sciences, Clinic of Infectious and Tropical Diseases, ASST Spedali Civili Hospital, University of Brescia, Brescia, Italy.
- Clinic of Infectious and Tropical Diseases, ASST Spedali Civili, Brescia, Italy.
- Department of Experimental Medicine and Public Health, Clinic of Infectious and Tropical Diseases, School of Advanced Studies, University of Camerino, Camerino, Italy.
Zitieren
APA
Calamelli, M., Davoli, C., Gerami, R., Gulletta, M., Lovatti, S., Pavesi, A., Rossi, B., & Matteelli, A. (2026). Cerebral and bone multidrug resistant tuberculosis treated with the BPaLM regimen: case report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1796484
Vancouver
Calamelli M, Davoli C, Gerami R, Gulletta M, Lovatti S, Pavesi A, et al. Cerebral and bone multidrug resistant tuberculosis treated with the BPaLM regimen: case report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1796484
BibTeX
@article{Calamelli2026,
author = {Calamelli, Marina and Davoli, Caterina and Gerami, Roberta and Gulletta, Maurizio and Lovatti, Sofia and Pavesi, Alessandro and Rossi, Benedetta and Matteelli, Alberto},
title = {Cerebral and bone multidrug resistant tuberculosis treated with the BPaLM regimen: case report},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1796484}
}
EUVIMED